Fortis Healthcare Limited

INR 1,657

e August 4, 2023 Fortis Healthcare reports Q1 FY24 Financial Results Consolidated revenues at INR 1,657 Crs, up 11.4%; Operating EBITDA margins at 16.5% Diagnostics Business of the company renamed as

rs,

4, 2023 Fortis Healthcare reports Q1 FY24 Financial Results Consolidated revenues at INR 1,657 Crs, up 11.4%; Operating EBITDA margins at 16.5% Diagnostics Business of the company renamed as “Agil

11.4%

Fortis Healthcare reports Q1 FY24 Financial Results Consolidated revenues at INR 1,657 Crs, up 11.4%; Operating EBITDA margins at 16.5% Diagnostics Business of the company renamed as “Agilus Diagn

16.5%

Financial Results Consolidated revenues at INR 1,657 Crs, up 11.4%; Operating EBITDA margins at 16.5% Diagnostics Business of the company renamed as “Agilus Diagnostics Limited” Board of Fortis & A

INR 1,488

enhance focus on key strategic clusters ➢ Consolidated Revenues for Q1FY24 at INR 1,657 Crs vs INR 1,488 Crs in Q1FY23, a growth of 11.4% ➢ Consolidated Operating EBITDA at INR 273 Crs versus INR 251 C

INR 273

INR 1,657 Crs vs INR 1,488 Crs in Q1FY23, a growth of 11.4% ➢ Consolidated Operating EBITDA at INR 273 Crs versus INR 251 Crs, a growth of 8.7% ➢ PBT prior to exceptional items at INR 169 Crs versus IN

INR 251

NR 1,488 Crs in Q1FY23, a growth of 11.4% ➢ Consolidated Operating EBITDA at INR 273 Crs versus INR 251 Crs, a growth of 8.7% ➢ PBT prior to exceptional items at INR 169 Crs versus INR 176 Crs ➢ PAT p

8.7%

growth of 11.4% ➢ Consolidated Operating EBITDA at INR 273 Crs versus INR 251 Crs, a growth of 8.7% ➢ PBT prior to exceptional items at INR 169 Crs versus INR 176 Crs ➢ PAT prior to exceptional i

INR 169

ng EBITDA at INR 273 Crs versus INR 251 Crs, a growth of 8.7% ➢ PBT prior to exceptional items at INR 169 Crs versus INR 176 Crs ➢ PAT prior to exceptional items at INR 122 Crs versus INR 134 Crs Consol

INR 176

3 Crs versus INR 251 Crs, a growth of 8.7% ➢ PBT prior to exceptional items at INR 169 Crs versus INR 176 Crs ➢ PAT prior to exceptional items at INR 122 Crs versus INR 134 Crs Consolidated Financial Sn

INR 122

prior to exceptional items at INR 169 Crs versus INR 176 Crs ➢ PAT prior to exceptional items at INR 122 Crs versus INR 134 Crs Consolidated Financial Snapshot Particulars (INR Crs) Q1FY24 Q1FY23

INR 134

al items at INR 169 Crs versus INR 176 Crs ➢ PAT prior to exceptional items at INR 122 Crs versus INR 134 Crs Consolidated Financial Snapshot Particulars (INR Crs) Q1FY24 Q1FY23 Revenue - Hospital

“By attending or assessing this presentation you acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.”

“There will be no public offering in the United States.”

Cash

2

For further details please contact

1

For further details please contact

Anurag Kalra / Gaurav Chugh Investor Relations +91-9810109253 / 9958588900 Fortis Healthcare Limited Ajey Maharaj Corporate Communication +91-9871798573 Fortis Healthcare Limited 4/4 FORTIS HEALTHCARE LIMITED EARNINGS PRESENTATION – Q1 FY24 August 04, 2023 DISCLAIMER This presentation may not be copied, published, distributed or transmitted. The presentation has been prepared solely by the company. Any reference in this presentation to “Fortis Healthcare Limited” shall mean, collectively, the Company and its subsidiaries. This presentation has been prepared for informational purposes only. This presentation does not constitute a prospectus, offering circular or offering memorandum and is not an offer or invitation to buy or sell any securities, nor shall part, or all, of this presentation form the basis of, or be relied on in connection with, any contract or investment decision in relation to any securities. Furthermore, this presentation is not and should not be construed as an offer

Cash

Domestic, 35.6% Pvt Corps, 0.9% Govt & PSUs, 10.2% International , 7.1% CGHS, 3.2% ECHS, 6.0% Pvt Corps, 0.9% Govt & PSUs, 9.4% CGHS, 4.0% ECHS, 6.9% International , 8.1% HOSPITAL BUSINESS PERFORMANCE – Q1FY24 All the key healthcare facilities continue to witness an upward momentum in revenues Revenue Q1FY23 Q1FY24 203 169 166 135 110 118 117 96 115 100 100 106 89 97 67 57 55 61 44 47 FMRI Mohali BG Road Noida Shalimar Bagh FEHI Mulund Anandpur Jaipur Faridabad Revenue Q4FY23 Q1FY24 201 203 166 153 115 118 116 117 114 115 112 106 105 97 72 67 61 48 47 47 FMRI Mohali BG Road Noida Shalimar Bagh FEHI Mulund Anandpur Jaipur Faridabad All figures in INR Crs. HOSPITAL MARGIN MATRIX EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy 20% - 25% 15% - 20% 10% - 15% <10% 3 7 4 8 36% 33% 10% 21% 968 1,367 552 1,184 2.87 2.09 1.53 1.93 73% 64% 68% 54% EBITDA No of Facilities Revenue Contribution Operational beds ARPOB (INR Cr) Occupancy >25% 20% - 25% 15% - 20%